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Summary
The aim of this report is to summarize the current state of the evidence from the sci-
entific literature regarding xerostomia. Xerostomia is a subjective complaint-symptom of 
dry mouth. It may be or may be not associated with objectively measured hyposalivation 
(reduction of saliva secretion). The variety of local and systemic conditions, treatments and 
medications alter salivary secretion and composition. The degree of salivary glands dysfunc-
tion as well as the accompanying oral morbidity as a complication of dry mouth, make 
xerostomia therapy complex and often refractory. 
Treatment of xerostomia essentially is carried out in regard to the cause and is divided in 
four main categories: palliative or symptomaic, local and systemic stimulation and preventi-
on of complications. Which  category will be applied, depends primarily on whether salivary 
glands can still produce saliva or not. In patients with residual salivary gland function, the 
use of salivary stimulans appears to be more beneficial than salivary substitutes. When saliva 
is absent, treatment remains palliative and must include salivary substitutes. During antican-
cer radio-and chemotherapy xerostomia is the earliest and the most prominent consequence 
which significantly affects the quality of life and lead to severe and long-term complications. 
Because management of xerostomia is rarely effective, prevention is paramount. 
Preventive measures should include acting on causes of xerostomia, maintaining sali-
vary function and  prevention of complications that arise in already developed xerostomia. 
Therapy of xerostomia depends on whether salivary glands function is preserved or not 
and includes local treatment and  systemic medications as well as non-medication salivary 
stimulation such as low level laser, acupuncture and electrostimulation. 
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SALIVA IN HEALTH AND DISEASE 
Saliva is essential for maintaining good oral and general health but people usu-
ally become aware of its presence and importance when they lost it. Deficiency or 
absence of saliva cause significant morbidity and lead to the reduction of a person’s 
quality of life (1-3).
Saliva is a complex fluid, mostly composed of water (99%) and in minor part of 
variety of non-organic and organic substances such as enzymes, hormones, antibo-
dies, antimicrobial constituents and growth factors.  Most of the constituents are 
produced within the glands; others are transported from the blood [1].
Salivary components provide the unique prophylactic, therapeutic and diagno-
stic properties of saliva.  It is well established that the composition of saliva reflects 
the oral and general health status [2-14]. Many of the compounds found in blood 
could be also detected in saliva, thus saliva is functionally equivalent to serum in 
reflecting the physiological state of the body, including emotional, hormonal, nutri-
tional, and metabolic variations [4]. A large number of medically valuable analytes 
in saliva are being gradually discovered and some of them represent biomarkers for 
different diseases such as periodontal disease [4],  oral cancer [5], breast cancer [6,7], 
autoimmune diseases [8], viral and bacterial diseases [9], HIV [10], cardiovascular 
diseases [11] and diabetes mellitus [12].
Due to the combination of emerging biotechnologies, such as molecular diagno-
stics and nanotechnology, saliva is becoming promising and increasingly valuable 
source of diagnostic information, e.g. biomarkers for early detection of the disease, 
and basis for the development of a dynamic and emerging field of salivary diagno-
stics [4,13,14].
In the mouth, saliva serves many purposes. It initiates and participates in dige-
stion, enchances masticatory function, facilitates swallowing and speech, improves 
taste, lubricates oral mucosa  and enables free movement of oral tissues and mainta-
ins mucosal integrity. Saliva facilitates irrigation and cleansing of the teeth and oral 
mucosa and with buffering capacity saliva protects teeth from demineralization and 
provides antimicrobial and immunological protection against oral infections in the 
mouth. Saliva is also critical for retention of and comfort in wearing dentures since 
the adhesion, cohesion and surface tension are interrelated and they all depend on 
the presence of saliva [1,2,15]. 
ASSESSMENT OF SALIVARY FLOW RATE 
Saliva is a product of three pairs of major salivary glands, parotid, submandibu-
lar and sublingual, as well as of hundreds of minor salivary glands distributed thro-
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ughout the oral cavity. Their respective estimated flow rates are as follows: parotid 
(65%~0.26 mL/min), submandibular (20%-30% ~0.08 mL/min), sublingual (6%~0.03 
mL/min) and minor salivary glands (5%~0.03 mL/min) [16]. 
Salivary flow rates provide essential information about salivary gland function. 
Saliva can be measured from each major gland or from a mixed sample of the oral 
fluids, termed whole saliva. To assess salivary gland secretion and oral dryness a 
variety of methods have been used, from self–reported  questionnaires (e.g. Xero-
stomia Inventory) [17-19],  visual analogue-scales (VAS), simple functional measures 
such as observing if a dental mirror adheres to the buccal mucosa or if a patient 
can chew and swallow dried biscuits without water to contrast sialography, sia-
loscintigraphy, sialoultrasonography, biopsy and sialometry of the minor salivary 
glands [20]. Eliasson et al. [21] performed measuring the volume of residual saliva 
on mucosal surfaces using filter paper and micro-moisture meter and calculating 
thickness and Takahashi et al. [22] used mucosal wetness (MW) devices. It has been 
shown that mucosal wetness measured by micro-moisture meter Periotron ® is a 
reliable measure of oral dryness and had a positive correlation with unstimulated 
whole saliva [23].  
However, sialometry is the most objective method  to assess salivary function 
and to determine the quantity of both resting and stimulated whole saliva. During 
sialometry, saliva can be collected by several methods including draining, spitting, 
suction, and absorbent (swab) method and measured. Whichever technique is cho-
sen for saliva collection, it is critical to use a well-defined, standardized, and clearly 
documented procedure [20,24].
Normal daily secretion of saliva is approximately á 1L to 1,5 L per day (i.e. 0,5 
mL/min -1 mL/min) although flow rate varies depending on diurnal variation, 
hydration, food intake and many other factors. Large variability in salivary flow 
rates within and between individuals has been reported, which has impaired the 
establishment of standard values. In a study of Ghezzi et al. [25] among 36 healthy 
males and females (18 young, ages 20-38; 18 older, ages 60-77) salivary flow rates 
varied 27-44% during a 6 hour period, suggesting that a 45% range in salivary flow 
rates could be considered normal salivary variation, and values below 45% of nor-
mal levels could be used to define salivary hypofunction. Salivary flow rate of un-
stimulated saliva less than  0.1 mL/min (measured for 5 to 15 minutes) and less than 
0.5 mL/min for the stimulated salivary flow respectively, is indicative for  salivary 
hyposecretion or hypofunction [26]. 
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HYPOSALIVATION AND XEROSTOMIA  
Salivary gland hypofunction or hyposalivation is the condition of having redu-
ced saliva production due to various causes. It usually leads to the subjective com-
plaint of oral dryness which is termed  xerostomia. The term xerostomia comes from 
the Greek word xeros (dry) and stoma (mouth), which means dry mouth. Dry mouth 
is one of the most common and most unpleasant  symptoms for which patients often 
seek help from a dentist or physician [18]. 
Dry mouth is a subjective feeling, not a distinct disease. Xerostomia is not a 
synonym for hyposalivation since it may also occur with the changes in the quality 
of saliva, while the amount of saliva stay unchanged. This is the reason that people 
sometimes complain of dry mouth but have proper salivation [3]. Therefore, a pa-
tient complaining of dry mouth cannot automatically be assumed to have salivary 
dysfunction, while oral dryness may have many causes [20]. Any individual may 
experience xerostomia with or without hyposalivation, experience hyposalivation 
with or without xerostomia or may have an average salivary flow and normal sen-
sation [17].
Oral dryness is one of the most common and most unpleasant oral symptom 
which adversely affects all oral functions and compromise oral health in any affec-
ted person. It leads to numerous oral sequelae including mucosal dryness, difficulty 
in chewing, swallowing and speaking, burning and pain of oral mucosa, propensity 
to damage of oral mucosa and infection, increased fungal infection, demineraliza-
tion of teeth and increase in caries, dysgeusia, halitosis and difficulty in wearing 
dentures. Therefore, for the maintaining good oral and general health, saliva should 
be secreted in an adequate quantity and quality [27]. 
PREVALENCE OF XEROSTOMIA 
Reports of the prevalence of xerostomia in general population are not conclusive 
and vary, ranging from 0.9% to 64.8%, mainly due to the small numbeof  studies in 
population-based samples [28].
However, the prevalence reaches almost 100% in patients with Sjögren’s syn-
drome and those who are receiving radiation therapy for head and neck cancer [29]. 
It has been shown that the prevalence increases with age and that xerostomia is 
more prevalent in postmenopausal women compared to men [16,30].  It is estimated 
that about 30% of the population older than 65 suffer from xerostomia [29]. Altho-
ugh previous opinion  that salivary function declines with aging process, it is now 
accepted that salivary flow as well as salivary constituens are both age-stable in the 
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absence of major medical problems and medications. Therefore, increasing age does 
not by itself cause hyposalivation [31].
As shown in the study of Murray Thomson W et al. xerostomia may be also a 
problem for a sizeable minority of young patients in early thirties, particularly those 
taking antidepressants who had 22 times higher risk for  xerostomia [32].  
Since there is no evidence that xerostomia is likely to result from the aging pro-
cess alone it can be concluded that the condition is a side-effect of various diseases 
and the drugs used to treat these diseases [29,33].
CAUSES OF XEROSTOMIA 
Xerostomia has a variety of possible causes [20].  In general, causes may be gro-
uped into two categories [34]: 
a) primary or direct causes comprise conditions that directly affect salivary glands 
and cause decreased salivary production [35]. These conditions include: Sjögren’s 
Syndrome; salivary gland diseases; endocrine conditions, such as type 1 and type 
2 diabetes mellitus as well as gestational diabetes; thyroid disease; adrenal conditi-
ons; renal or hepatic diseases; infections with hepatitis C virus and HIV. 
Sjögren’s Syndrome (SS) is the most common autoimmune disease characteri-
zed by inflammation of the exocrine glands and may occur independently (as pri-
mary Sjögren’s syndrome or Sycca syndrome limited to the eyes and mouth, SS-1 
) or in association with other autoimmune diseases such as rheumatoid arthritis, 
systemic sclerosis or systemic lupus erythematosus (secondary Sjögren’s syndrome 
that affets connective tissue, SS-2). The prevalence of Sjögren’s syndrome  is 1% to 
4% in older adults and is more common in postmenopausal women [36].
The study of Pijpe et al. [37] showed that duration of Sjögren’s syndrome is in 
positive correlation with severity of xerostomia; patients with Sjögren’s syndrome 
with longer disease duration are characterised by severely reduced secretions of, 
firstly the parotid, and then submandibular and sublingual gland. Authors conclu-
de that these observations are relevant for identifying patients who would most 
likely benefit from intervention treatment. 
When an autoimmune disease is suspected, a minimally invasive technique of 
minor salivary gland biopsy of the lower lip should be made with the determination 
of serum antibodies [38].
In Sjögren’s syndrome the progressive lymphocytic infiltration gradually de-
stroys the secretory acini of the major and minor salivary glands which results in 
hyposalivation and finally in xerostomia. Another explanation for the loss of glan-
dular function may be related to an inhibition of nerve stimuli of the glands [39].
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The hypofunction of egzocrine glands causes  dryness of mucosal surfaces, 
most noticeable of the mouth and eyes [36]. 
b) Secondary or indirect causes of xerostomia are conditions of which hyposaliva-
tion or oral dryness are side effects. 
Xerostomia and salivary gland hypofunction are major complications of radia-
tion- therapy (RT) or chemotherapy. Head and neck radiation RT is employed as a 
primary, concomitant or adjuvant treatment modality for primary and recurrent 
tumors of the head and neck region. Irradiation and cytostatic drugs lead to sialoa-
denitis which in turn may lead to irreversible damage of acinar cells of major and 
minor salivary glands and result in hyposalivation and permanent xerostomia [1]. 
Long-term morbidity in patients receiving combined radiation and chemotherapy is 
significant because of salivary gland hypofunction, radiation-induced xerostomia, 
mucositis and severe dysphagia [20].
Although radiotherapy was earlier considered the most common cause of sali-
vary gland hypofunction and xerostomia, in recent years medications have emer-
ged as the most common cause, particularly in elderly people. It has been shown 
that among the most commonly prescribed drugs 80% of them cause xerostomia 
with more than 500 medications causing  an adverse effect of dry mouth [2,16,20,40]. 
Xerostomic drugs can be found in 42 drug categories and 56 subcategories [33]. 
(Table 1). The most common medications causing hyposaliva tion are those with an-
ticholinergic activity, sympatomimetics and benzodiazepines [2]. These are also 
the most commonly prescribed medications in geriatric population. The risk for 
xerostomia  will increase the synergistic effects of xerogenic medications, multiple 
medications (polypharmacy), higher dose of medication and the time of starting the 
medication. This is the main reason that the prevalence of medication-induced xe-
rostomia is highest in the elderly. 
Salivary gland hypofunction and chronic xerostomia can also be side effect of a 
variety of autoimmune disorders (other than Sjögren’s syndrome), such as rheuma-
toid disorders, scleroderma, mixed connective tissue disease  and systemic erythe-
matous lupus [41], advanced stages of HIV infection [42], endocrine disorders, such 
as uncontrolled diabetes and thyroid and adrenal gland diseases [43], graft versus 
host disease (GVHD) following allogeneic [44], or autologous hematopoietic stem 
cell transplantation [45], malnutrition and protein deficiency in anorexia and buli-
mia (20), chronic or neurogenic pain, smoking tobacco and cannabis [46], consuma-
tion of drugs of abuse [47], drinking alcohol or caffeine-containing fluids, sleeping 
with open mouth or mouth breathing at any time, such as during nasal congestion 
and using inhalers, iatrogenic procedures and regimens, (anesthesia, intubation/
ventilator-assisted breathing, intravenous feeding etc) [1,2,16,34]. 
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Dehydration of the organism can secondarily affect salivation, and changes in 
the quantity of water in the body can affect the wetness of oral mucosa  which may 
create a feeling of dry mouth [2,20,29,34]. The feeling of dry mouth can occur also 
due to the change in cognitive abilities of the central nervous system following a 
cerebral vascular accident (stroke) (48) and sensory disturbances in the mouth. Alte-
rations in autonomic innervation of salivary glands with predominant sympathetic 
stimulation, during episodes of acute anxiety or stress, cause changes of salivary 
composition  that creates sensation of oral dryness. There are also psychological 
conditions that lead to feeling of oral dryness such as depression and insomnia as 
well [2, 29, 33, 34, 48]. 
Table 1.  Drugs associated with dry mouth (2)
Drugs that directly damage salivary glands
Cytotoxic drugs
Drugs with anticholinergic activity
Anticholinergic agents: atropine, atropinics and hyoscine








Drugs acting on sympathetic system
Drugs with sympathomimetic activity (e.g., ephedrine)
Antihypertensives: 
alpha-1 antagonists (e.g., terazosin and prazosin); alpha-2 agonists (e.g., 
clonidine); may reduce salivary flow
beta blockers (e.g., atenolol, propanolol), which also alter salivary protein 
levels
Drugs that deplete fluid
Diuretics
RADIATION-INDUCED XEROSTOMIA 
Xerostomia is one of the most common complications during high-dose radia-
tion therapy (RT) for head and neck cancer (HNC) and  has a significant impact on 
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quality of life, requireing careful planning of long-term dental and oral care. Stan-
dard RT for advanced head and neck cancer involves fractionated doses of 10 grays 
(Gy) weekly (2 Gy daily on 5 consecutive days) over 5 to 7 weeks to a total dose of  50 
to 70 Gy. Parotid glands exposed to doses of greater than 60 Gy sustain permanent 
damage with no recovery in salivary hypofunction with time [20].
Radiotherapy (RT) of the head and neck region causes both acute and long-term 
complications on salivary gland tissue and function, as well as radiation-induced 
compositional salivary change [49]. 
 Acute effects of radiation on salivary function occurs during the first week of RT 
and deterioration continues until flow rates are barely measurable at 6 to 8 weeks. 
Frequently seen acute accompanying oral side effects include mucositis, dysphagia, 
erythema and desquamation of oral mucosa. Late complications are result of cronic 
injury on exposed tissue; mucosa, vasculature, salivary glands, connective tissue 
and bone. The type and severity of these changes are related directly to total dose 
administered, fraction size and duration of the treatment as well as  on volume of 
irradiated tissue. Qualitative changes in saliva include increased viscosity, increased 
organic component, altered pH, decreased transparency, and yellowbrown discolo-
ration [50].
Radiation-induced xerostomia starts in the first week of RT during which sali-
vary flow decrease for 50%-60% and  after 7 weeks of RT diminishes to aproximately 
20% [51]. Salivary function continues to decline for up to several monts after RT [50].
The assessment of the severity of xerostomia in patients with head and neck 
cancers after radiotherapy and its effect on quality of life (QoL) over a period of 6 
months, in a study of Kakoei et al. [52] showed that QoL significantly worsened with 
increased time along with  the severity of xerostomia which increased significantly. 
With each milliliter decrease in saliva secretion, the QoL score decreased 2.25%. 
With one score increase in xerostomia, from the QoL mean score there was a 1.65% 
decrease. [52]. 
Even though, some recovery is possible after 12 to18 months  after RT, with incre-
ase in salivary flow up to 32% from 1 to5 years after treatment [53], depending on the 
dose received and volume of the gland tissue irradiated, xerostomia  develops into 
an irreversible, life-long health problem that significantly reduces quality of life for 
the patients. It was also shown when multiple daily treatments are given in small 
fractionated doses (<1,8-2 Gy) this does not increae the incidence of xerostomia [20]. 
It is obvious that the quality of life in patients who underwent radiotherapy in 
the head and neck region is  strongly influenced by xerostomia and all its consequ-
ences. Patients usually suffer from dry, vulnerable and painful oral mucosa, have 
difficulties in all oral functions (chewing, swallowing and particularly speech), per-
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ception of taste is altered or even  partially lost. The risk for dental caries increases 
secondary to number of factors: shift to cariogenic flora, reduction of salivary pH, 
and loss of mineralizing components. The reduction in salivary flow may contribute 
to the risk of fungal infection and osteonecrosis of the mandible. All these secon-
dary effects of radiation-induced xerostomia contribute to the so-called xerostomia-
syndrome [54]. 
COMPLICATIONS OF XEROSTOMIA  
Dry mouth has multiple oral health consequences and affects quality of life (Ta-
ble 2) [33]. Patients with xerostomia may be asymptomatic  without complaints, or 
more frequently, complain of dry mouth and develop various complications. Pati-
ents usually experience difficulties while speaking, chewing, swallowing (dyspha-
gia) and wearing dentures [1-3,15,20,34]. 
Oral mucosa is dry and sensitive, prone to injuries, fungal infection and in-
flammation, painful with burning sensations, taste is altered and halitosis is pre-
sent. In patients with Sjogren’s syndrome in which exocrine glands and the connec-
tive tissue is affected patients complain about the dryness of the eyes. The parotid 
glands become visibly enlarged. These initial changes may precede clinical eviden-
ce of mucosal changes or measurable reduction in salivary gland function [36].
In the patient with dentures and insufficient saliva, the lack of lubrication can re-
sult in traumatic ulcerations of the mucosa, and increased susceptibility to oral fun-
gal infection, candidosis. Various treatment modalities have been suggested in the 
literature to overcome the problem of xerostomia in complete denture patients. In-
corporating reservoirs containing salivary substitutes into dentures is one of these 
treatment modalities. Dabas et al. [55] described new split denture technique which 
resulted in a reservoir denture that provided good lubrication of the oral tissues, can 
be  easily cleaned by the wearer and can be  produced from routine denture mate-
rials. In addressing such issues Murthy et al. [56] describes a new method by using 
flexible complete denture construction in radiation induced xerostomic patient with 
minimal tissue damage during and after denture construction procedures.
Lack of saliva increases the risk of developing caries (particularly at the cervi-
cal and root areas of the teeth), enamel erosions and  periodontal diseases [1,2,33]. 
Study of  Yeh et al. [57] provided the evidence that hyperglycemia in combination 
with reduced saliva in a model of type1 DM leads to decreased enamel mineraliza-
tion/matrix proteins and predisposes to excessive wearing and decay. Importantly, 
hyperglycemia adversely affects enamel matrix proteins and pulp repair. Early de-
tection and treatment of hyperglycemia and hyposalivation may provide a useful 
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strategy for preventing the dental complications of diabetes and promoting oral he-
alth in this population. 
Oral fungal infection (candidosis)  and enlargement of salivary glands from si-
aladenitis are seen commonly in patients with moderate-to-severe salivary gland 
hypofunction [2,20]. The risk of infection is increased in people who wear dentures, 
smokers and diabetics; in patients with Sjögren’s syndrome and connective tissue 
diseases treated with corticosteroids or other immunosuppressants. These drugs 
also contribute to candidiasis because they reduce the natural resistance of the 
mucosa. Lack of saliva creates difficulties in wearing dentures while promoting the 
development of denture stomatitis [1,2].
Table 2. Consequences and complications of xerostomia
Dry mouth
Thirst






Injuries of oral mucosa
Oropharyngeal burning
Mucus accumulation
Food retention in the mouth
Plaque accumulation
Hyposalivation-associated caries




TREATMENT OF XEROSTOMIA 
Treatment of xerostomia depends on the cause and the degree of damage of the 
salivary glands, thus it comprises etiologic, stimulative, symptomatic or palliative 
approach. Current therapies include saliva substitutes and saliva stimulans (siala-
gogues). In cases when there is still some residual salivary function it was shown 
that saliva stimulans (local or systemic stimulation of secretory gland) produce 
greater relief than saliva substitutes. When salivary glands are irreversible dama-
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ged and without capability to produce saliva, as is in the cases of head and neck ra-
diotherapy or advanced systemic disease (e.g. Diabetes mellitus, Sjögren sy)  pallia-
tive treatment remains the option. 
When salivary function is preserved stimulation of salivary glands aimed to 
increase the salivary output, include:  
1. Local stimulation
The combination of chewing and acidic taste, as provided by chewing gums or 
solid food or fruits, preferentially acidic (apple, pinneapple, carrots etc.) can be very 
effective in stimulating saliv flow  for patients who have remaining salivary functi-
on. Patients with dry mouth must be told not to use sweets, sweetener in food and 
drink and various other sugar products due to the increased risk for dental caries. 
Acidic soft drinks are an increasing source of dental erosion as is excessive intake of 
white wine 
The use of laser infrared light of 904nm (low level laser therapy, LLLT) on sa-
livary glands in the treatment of xerostomia proved to be not only stimulative but 
also regenerative in nature [58]. 
Use  of acupuncture in the treatment of xerostomia have focused earlier mainly 
on a curative approach when the salivary gland tissues are already damaged and 
xerostomia is present. Recent study by Braga et al. [59] showed that acupuncture can 
be used efficiently as preventive approach in the management of patients with head 
and neck cancer undergoing RT. Although preventive acupuncture  approach did 
not prevent the oral sequelae of RT completely, it significantly minimized the sever-
ity of radiation-induced xerostomia.
Electrical stimulation has also been used as a therapy for salivary hypofunction 
but has been inadequately investigated clinically. A device that delivers a verylow-
voltage electrical charge to the tongue and palate has been described although its 
effect was modest in patients with dry mouth [16]. 
2. Systemic stimulation 
Any agent that has the ability to influence salivary glands to increase production 
of saliva is termed a secretagogue. Among  24 examined agents  only four sialagogues 
have been examined extensively in controlled clinical trials; these are bromhexine, 
anetholetrithione, pilocarpine hydrochloride (HCl), and cevimeline HCl, but with 
mixed results [20].
The mechanism of action for salivary stimulation of a mucolytic agent bromhexine 
and anetholetrithione is not fully understood. No proven benefit to salivary function 
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has been shown for bromhexine yet it may stimulate lacrimal function in patients 
with Sjögren’s syndrome although this is controversial. It has been suggested that 
anetholetrithione may up-regulate muscarinic receptors and increased saliva flow 
in patients with mild salivary gland hypofunction, but was ineffective in patients 
with marked salivary gland hypofunction. 
Pilocarpine HCL is the best studied sialagogue. As a parasympathomimetic agent 
it causes stimulation of cholinergic receptors on the surface of acinar cells.  Pilocar-
pine increases salivary output, stimulating any remaining gland function. Current 
indications are for patients following radiotherapy and for those with Sjögren’s syn-
drome. In doses of up to 15 mg/day, it increases secretion of saliva, and for optimal 
results  patients should be treated during 8-12 week. After the administration of 
pilocarpine, salivary output increases rapidly, usually reaching a maximum within 
1 hour. The best-tolerated doses are those of 5.0 to 7.5 mg, given three or four times 
daily. The duration of action is approximately 2 to 3 hours. [20]. Pilocarpine may be 
used as maintenance therapy during longer periods and as a salvage therapy for sa-
livary gland function during RT. Stimulation of the salivary glands during radiation 
therapy has been suggested as a possible means of reducing damage to the glands. 
The synergistic effect of anetholetrithione in combination with pilocarpine was 
shown [20]. The mechanism of action of anetholetrithione may be to increase the 
number of cell surface receptors on salivary acinar cells and  pilocarpine stimulates 
the receptors thus, in combination, these  drugs have synergistic effect [20]. Pilocar-
pine is contraindicated in patients with pulmonary disease, asthma, cardiovascular 
disease, gastrointestinal diseases and glaucoma [20].
Cevimeline is another parasympathomimetic agonist that has been recently 
approved for the treatment of oral dryness in patients with Sjögren’s syndrome. Due 
to similar side effects as to those of pilocarpine it must be prescribed with caution.
3. Symptomatic  approach 
Palliative treatment remains as only choice in cases when there is no functio-
nally salivary tissue present as is in the disorders of irreversible damage of salivary 
secretory cells (such as in radiation-induced xerostomia). Most remedies available 
today for patients with dry mouth are only symptomatic and aimed to avoid or alle-
viate discomfort and pain as well as to prevent complications of xerostomia.  
A number of saliva substitutes have been developed for the palliative care of 
patients with salivary hypofunction to supplement the saliva and alleviate oral 
symptoms of dryness. These agents, in liquid, spray, or gel form have moistening 
and lubricating properties, and their purpose is to provide prolonged wetness of 
the oral mucosa. Commercial artificial saliva should resemble normal saliva in its 
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biophysical properties. Preetha and Banerjee [60] compared artificial saliva based on 
carboxymethylcellulose and the xanthan gum and found that the examined  sub-
stitutes fall short of required biophysical criteria and modifications are required to 
improve them.
The advantages of saliva substitutes or artificial saliva are in the coating and 
moisturizing oral mucosa and teeth, and disadvantages are their  short-term acti-
vity  without  preventive effect on oral tissue. Commercialy available alcohol contai-
ning oral rinses should be avoided due to their drying effect. As shown in the study 
of Gil-Montoya et al. [61] the evaluated mouthwash and oral gel as saliva substitutes 
may improve some subjective and clinical aspects in elderly individuals with dry 
mouth, although a placebo effect cannot be entirely discarded.
Patients with irreversible xerostomia should be instructed to maintain proper 
hydration of the oral cavity by taking plenty of fluids throughout the day and kee-
ping the mouth moist, and using artificial saliva preparations.  Frequent sips of wa-
ter throughout of day and during the meals will facilitate chewing  and swallowing 
and may also improve the taste of food. The use of bedside humidifiers may lessen 
discomfort of dryness, especially at night during sleep when any residual salivary 
secretion is physiologically decreased. Patients should avoid any caffeinated drinks 
(tea, coffee) and soft drinks and alcohol, as well as smoking and alcohol-containing 
mouthwases to prevent further desiccation. Special denture adhesives for individuals 
with xerostomia also may provide some retention aid for removable dentures. Peri-
odontal diseases may be prevented by using an alcohol-free, antibacterial mouth rinse, 
such as chlorhexidine. 
Professional oral hygiene procedures and instructions in home care as well as di-
ligent and meticulous oral hygiene are crucial to reduce the bacterial load in the oral 
cavity and thus the risk for halitosis and oral infection. Oral care is also important 
for the patient’s general health (Table 3).
PREVENTION OF XEROSTOMIA 
There are several options how to prevent development of xerostomia or decre-
ase its severity: 
a) Acting on the cause of xerostomia – possible adjustment of medications and 
possibly amelioration or elimination of the underlying cause
In the case of drug induced xerostomia - it is important to discuss possible pres-
cription of alternative drugs with less desiccative side effects, decreasing the dose 
of prescribed drug or the number of xerogenic drugs (particularly in the case of 
poypharmacy).
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Table 3. Treatment of xerostomia by dental professionals and recommendations to patient [34]
All patients with 
xerostomia Actions by Dental Care Provider Recommendations to Patients 
 Conduct careful medical history 
Carefully record ALL medications 
(type, dosage, frequency, start  
date)* 
Inquire regarding compliance with 
medicine regimen prescribed 
Conduct thorough oral 
examinations and keep in mind all
possible underlying causes 
deducted from any source, 
Casual conversation with patient: 
- Medical history 
- Medication use 
- Oral signs, symptoms, lesions, 
- Dentures 
 
Proper oral hygiene 
Do not brush teeth immediately 
upon wakening when thin surface 
layer of enamel is slightly softened 
due to acidic activity and lack or 
liquid intake during sleep 
Sip water frequently 
Rinse mouth with plain water 
during eating & drinking 





rinse without alcohol 
Avoid alcoholic and caffeinated 
beverages 
Discontinue tobacco smoking, 
 
Use a humidifier at night 
Use salivary flow stimulants: 
sugarless  gum, hard candy, or 
lozenges 
Use palliative saliva substitutes, 
Such as: liquids, gels, sprays
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Decreasing dosage of psychopharmaca could be attained by psychotherapy or 
adding a light exercise regimen to the patient.
For a patient with uncontrolled type 2 diabetes, regular glycemic control (using 
modifications of diet, exercise, and possibly oral anti-diabetic medication or insu-
lin), may eliminates the hypo-salivation. Xerostomia being caused by uncontrolled 
diabetes, can be cured by bringing diabetes under control.
b) Maintaining salivary function - Certain patients with hyposalivation may 
benefit from administration of medications that stimulate salivary output 
(sialagogues such as  pilocarpine or cevimeline if there is no contraindicati-
ons for these medications) 
In a 30-week longitudinal study of women with Sjögren’s Syndrome, daily doses 
of 400 mg hydroxychloroquine were found to increase unstimulated, but not stimu-
lated, salivary flow rate. Hydroxychloroquine is classified as an anti-malarial medi-
cation and is also used to decrease inflammation in systemic lupus erythematosus 
as well as rheumatoid arthritis and Sjögren’s Syndrome (all rheumatic disorders) 
[62]. 
PREVENTION OF RADIATION-INDUCED XEROSTOMIA 
 Several strategies have been developed to avoid radiation-induced salivary 
dysfunction without compromising oncologic treatment. They include parotid 
gland sparing RT, cytoprotectants and surgical salivary gland transfer. However, 
each of these approaches have some limitations. 
a) Parotid-gland sparing radiotherapy. This therapeutic approach focuses the ra-
diation beams to the target tumour tissue with aim to avoid unnecessary 
radiation of sourrounding salivary gland. This was enabled by the  imple-
mentation of  3-dimensional (3D) conformal RT (3D-CRT) and intensity mo-
dulated RT (IMRT) techniques in clinical practice.  IMRT is based on com-
puter-optimized treatment planning and a computer-controlled treatment 
delivery system. The computer-driven technology generates dose distribu-
tions that sharply conform to the tumor target while minimizing the dose 
delivered to the surrounding or contralateral normal gland tissues. Multiple 
studies have demonstrated that the parotid gland sparing effect of this tre-
atment modality resulted in significant objective and subjective improve-
ment of xerostomia. However, in patients who have tumours that originate 
from the midline or that cross the midline, or in patients with contralateral 
lymph node metastais it is not possible to use this technique [54,63]. 
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b) Cytoprotectants - several agents have been developed to protect normal ti-
ssue against cytotoxic effects of RT and/or chemotherapy among which the 
most investigated is radioprotector amifostine. In active form it enters into 
the cells and nuclei where it acts as a scavenger against free radicals thus pre-
venting radiation damage of DNA. Evidences from the recent studies show 
cytoprotective effect of amifostine:  
- on the salivary gland during RT (amifostine is effective in preventing 
acute and late xerostomia in head and neck cancer patients); 
- on oral health (unchanged DMFT (Decayed-Missing-Filled Teeth) index 1 
year post-RT; trend to decreased incidence of oral candidiasis during ami-
fostine cytoprotection; together with reduced xerostomia, amifostine  may 
concomitantly help delay the onset of severe mucositis) [63].
However, a high rate of serious adverse events, including hypotension and ga-
strointestinal disturbances, results in discontinuation of amifostine and limits its 
use.
c) Salivary gland transfer – this technique propose surgical transfer of 1 sub-
mandibular gland to the submental space outside the path of radiation. This 
procedure has limitations: if patient refuse surgical treatment; if patient is 
not planned to receive postoperative RT; and if submental space is involved 
with tumour [64].
PREVENTION OF XEROSTOMIA COMPLICATIONS  
Prevention of complications is carried out in all patients with dry mouth, and 
aims to prevent development of caries, oral fungal infection and stomatitis.
Caries 
Fluoride preparations for control of dental caries should be prescribed to all 
individuals who have natural teeth. Patients with significant xerostomia should be 
closely monitored for the development of dental caries, which may be prevented 
by the daily use of 1.1% sodium fluoride (NaF) dentifrice or gel.  Application of flu-
oride should be adjusted accordingly to the severity of the gland dysfunction, the 
degree of development of caries and the underlying disease or the cause that led 
to the dryness of the mouth. Studies have demonstrated that fluoride preparations 
alone are not sufficient to prevent caries and remineralization of damaged teeth, 
particularly in patients with dry mouth who underwent radiation therapy [65-67]. 
A study evaluated the use of calcium phosphate supersaturated remineralizing rinse in 
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tandem with 1.1% NaF for daily use in patients at high risk for caries due to xerosto-
mia [67]. Artificial saliva, supersaturated remineralizing rinse based on calcium and 
phosphate ions (Caphosol® ,EUSA Pharma, USA) was developed to treat patients on 
radio-and chemotherapy and to prevent the development of mucositis [65].
In a xerostomic group, a regimen of Caphosol® used daily with 1.1% sodium 
fluoride dentifrice, and fluoride varnish treatments every 3 months was effective in 
preventing the progression of both root and coronal caries and significantly increa-
sed net reversals or remineralization [66,67]. 
Fungal infections (candidosis) 
 Treatment of oral candidosis with topical antifungal medications from polyenic 
group such as nystatin and amphotericin B proved to be successful at the beginning 
of the therapy. During the treatment, adverse effects of drugs were observed in some 
patients, and in patients treated with anticoagulant drugs and antidiabetics the use 
of antifungal drug myconazole is contraindicated. In xerostomic patients  after cesa-
tion of the antifungal therapy relapses of oral infection are common [20]. A combi-
nation of antifungal drugs and application on the surface of dentures was described 
in patients with dentures and denture stomatitis. Other studies have shown that 
pretreatment isolates of C. albicans with polyenic antifungals reduces its ability to 
adherence to denture acrylic surfaces, and also prevents the adhesion of Candida to 
buccal epithelial cells [20].
In recent study the effect of supersaturated solution of calcium and phosphate 
(Caphosol®) on oral yeast infection in patients with dry mouth was investigated. Su-
persaturated solution of calcium and phosphate increased the amount of saliva and 
significantly reduced oral fungal infection, in comparison with a solution of sodium 
bicarbonate. Compared with myconazole and in combination with it, no significant 
differences were found [68].
Dentures wearing
In dentures wearing patients wetting dentures before placing them into 
the mouth and spraying protheses with artificial saliva before applying dentu-
re adhesives [15] will help in reducing the discomfort. Use of salivary substitutes 
(e.g.marshmallow tea) and artificial saliva will help in adhesion, stability and den-
ture retention. Wetting dentures before meals and taking more fluids during meal-
time will aid in mastication and swallowing [1-3,20,24,34]. Adapted denture fabrica-
tion (split denture technique and flexible complete denture construction) will help 
in alleviating dyscomfort [55,56].
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CONCLUSION 
Oral health and function depend on salivary function. Although xerostomia is 
common in elderly patients it is frequently not assessed and managed  on time. Due 
to serious complications of dry mouth which affects oral and general health the qua-
lity of life of these patients is decreased. Therefore, the assessment of salivary gland 
hypo-function, early recognition, prevention and treatment of xerostomia and its 
complications will need to be incorporated into everyday clinical dental practice. 
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Sažetak
Kserostomija – dijagnostika i liječenje
Kserostomija je subjektivan osjećaj suhoće usta koji nastaje zbog smanjenog lučenje 
sline ili hiposalivacije. Smanjeno lučenje sline je posljedica oštećenja žlijezda slinovnica 
koje uzrokuju određeni sustavni poremećaji, brojni lijekovi i liječenje zračenjem tumora u 
području glave i vrata. Raznolikost uzroka hiposalivacije, stupanj oštećenja slinovnica te po-
pratni oralni morbiditeti kao komplikacije suhoće usta, čine terapiju kserostomije složenom, 
a često i refraktornom. 
Liječenje kserostomije ovisi o uzroku i stupnju oštećenja slinovnica i obuhvaća simp-
tomatsko liječenje, lokalnu i sustavnu stimulaciju žlijezda slinovnica i prevenciju komplika-
cija. Izbor liječenja ovisi o stanju slinovnica i mogućnosti stvaranja sline. U osoba u kojih 
je funkcija slinovnica očuvana, provodi se stimulativna terapija dok se u osoba u kojih su 
slinovnice ireverzibilno oštećene i koji nemaju sline provodi nadomjesno liječenje umjet-
nom slinom i simptomatsko liječenje. Kserostomija je jedna od prvih i teških komplikacija 
liječenja zračenjem raka glave i vrata i kemoterapije. 
Prevencija kserostomije obuhvaća djelovanje na uzrok kserostomije i održavanje sa-
livarne funkcije i prevenciju komplikacija. U prevenciji radijacijske kserostomije razvijeno 
je nekoliko strategija liječenja koje uključuju sofisticirane kirurške tehnike, citoprotektivna 
sredstva i posebne tehnike ozračivanja pri čemu se štedi tkivo slinovnica a istodobno ne 
ugrožava onkološko liječenje. Međutim, ovi preventivni postupci ne mogu se primjeniti u 
svih pacijenata pa u konačnici jedini izbor je liječenje suhoće usta. Dostupni načini liječenja 
kserostomije obuhvaćaju više kategorija, a izbor terapijskog postupka ovisi o tome da li sli-
novnice mogu stvarati slinu ili ne. U nemogućnosti stvaranja sline primjenjuju se nadomjest-
ci sline i umjetna slina. Terrapija kserostomije uz lokalnu i sustavnu terapiju uključuje i 
fizikalne metode stimulacije slinovnica kao što su laser, akupunktura i elektrostimulacija. 
Ključne riječi: suhoća usta; kserostomija; hiposalivacija; sijalometrija; kserostomija/oral-
ne komplikacije; kserostomija/etiologija; kserostomija/prevencija; kserostomija/liječenje; 
umjetna slina; prezasićena remineralizirajuća otopinakalcija i fosfata.
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